Sustained Complete Response to a Short Course of Subcutaneous Daratumumab in Multi-Refractory Immune Thrombocytopenia. Mediterr J Hematol Infect Dis [Internet]. 2026 Sep. 1 [cited 2026 Sep. 2];18(1):e2026069. Available from: https://www.mjhid.org/mjhid/article/view/6466